ERBB2 and breast cancer: The high prevalence of ER+/PR+ tumours associated with the presence of pembrolizumab-responsive ADCC-capable immune cells (Supplementary Fig. 5) warrants further investigation, especially given recent interest in assigning “triple positive” breast cancer (ER+/PR+/HER2+) as a distinct subtype [52].